Using personalized medicine to avoid resistance to leukemia treatment
Hospital doctor who took {pound}41 000 in salary payments after contract ended loses appeal against erasure
4 May 2021Child abuse hotline volume up during pandemic
4 May 2021Using personalized medicine to avoid resistance to leukemia treatment
T-cell acute lymphoblastic leukemia (T-ALL) is a very aggressive type of blood cancer. It is relatively rare but still draws a lot of attention as it mostly develops in children under the age of 20. The standard treatment for T-ALL involves heavy chemotherapy procedures, which result in favorable outcomes with an overall survival of 75% after 5 years.
